Skip to content

WoundVac in Obese Patients Undergoing Lumbar Surgery

Post Operative Wound Complications in Patients With BMI ≥35kg/m2 After Posterior Lumbar Spine Surgery: a Randomized Clinical Trial of Closed-Incision Negative-Pressure Therapy

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03688438
Enrollment
124
Registered
2018-09-28
Start date
2018-10-15
Completion date
2020-10-15
Last updated
2018-09-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lumbar Spine Surgery, Obesity

Brief summary

This is an open label, randomized clinical trial of Closed-Incision Negative-Pressure Therapy to decrease post-operative wound complications in patients with BMI ≥35kg/m2 after posterior lumbar spine surgery.

Detailed description

Methods: Study Design: Prospective open-label randomized clinical trial of CINPT in obese patients. Subjects will be randomized in a 1:1 to Standard of Care (SOC) and CINPT. Study Arms: (1) Standard of Care (2) CINPT Sample Size: Based on 30% incidence of wound complications in obese patients undergoing lumbar spine surgery, a sample size of 124 (62 in each cohort) will be needed to detect a decreased incidence of 10% with an α of 0.05 and β of 0.2. Randomization: Randomization will be done with varying blocks of 4, 6 and 8 using opaque sealed envelopes. Procedures: All patients will receive standard pre operative prophylactic antibiotics with 2g - 3g Cefazolin or 1g Clindamycin (if patient has known penicillin allergy) based on weight 60 min before incision is made. They will be clipped if needed before being prepped. Each patient will be prepped with alcohol and then either duraprep, chloraprep, or betadine. After the procedure is complete, a subfascial and subcutaneous closed suction drain will be placed in the wound prior to closure. 1 to 3 gram of Vancomycin powder will be placed in the wound. The wound is closed with #1vicryl for the fascial layer followed by 2-0 Vicryl for the subcutaneous layer followed by 3-0 or 4-0 monocryl. In the SOC group, skin glue, Steri-strips, sterile gauze and Tegaderm will be applied to the wound. In the CINPT group, a CINPT dressing will be placed and attached to a compact portable negative pressure unit to deliver 125mmHg continuous pressure for 5 to 7 days. All patients will receive standard wound care instructions before hospital discharge. Patients will return to the clinic in 6±1 days for a wound check and removal of the CINPT. Primary endpoint: The primary endpoint is the occurrence of a wound complication. A wound complication can include a local inflammatory reaction, wound dehiscence, skin blistering/necrosis, stitch abscess or Incision and drainage for hematoma seroma, deep or superficial infection

Interventions

DEVICEClosed-Incision Negative-Pressure Therapy

A foam or gauze dressing is put directly on the wound. This foam acts as a filter to keep any large particles (such as blood clots or dead, sloughed off tissue) from clogging the vacuum system. A clear, occlusive, adhesive film covers and seals the dressing and wound, creating an airtight seal. A drainage tube leads from under the adhesive film and connects to a portable vacuum pump. This pump removes air pressure over the wound. The pump is programmed for strength of suction, amount of time it is to be applied and if it is to be intermittent or continuous. A chamber on the pump collects drainage and moisture is drawn away from the wound site.

Sponsors

Norton Leatherman Spine Center
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE

Intervention model description

Two study arms: (1) Standard of Care and (2) WoundVac

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Adult patients aged ≥18 years old * Patients undergoing posterior lumbar fusion with or without interbody fusion * Body Mass Index of ≥35kg/m2 * Able to provide Informed Consent * No prior lumbar spine surgery

Exclusion criteria

* Presence of skin infection or any systemic infection * Known allergy or sensitivity to silver or acrylic adhesive * Fragile peri-incisional skin * Patients on anti-coagulation and/or platelet aggregation inhibitors

Design outcomes

Primary

MeasureTime frameDescription
Incidence of wound complicationWithin one month after surgeryA wound complication can include a local inflammatory reaction, wound dehiscence, skin blistering/necrosis, stitch abscess or Incision and drainage for hematoma seroma, deep or superficial infection

Secondary

MeasureTime frameDescription
Days to dry woundOne month after surgeryNumber of days after surgery it took to have the wound become dry

Countries

United States

Contacts

Primary ContactLeah Y Carreon, MD, MSc
spineresearch@nortonhealthcare.org5029920488
Backup ContactKelly R Bratcher, RN
kelly.bratcher2@nortonhealthcare.org5029920488

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026